Spinex Inc.
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- spinex.co
- Founded
- 2018
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 59 Miscellaneous Retail
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Research Institute At Nationwide Children's Hospital | P50FD007961 | $50,000 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Transtimulation Research Inc. | Oklahoma City, OK | — |
| Teliatry Inc. | Richardson, TX | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Ecate, Inc. | Los Angeles, CA | 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing |
| Dignify Therapeutics, LLC | Durham, NC | — |
| Axonova Medical Inc. | Philadelphia, PA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Spinex Inc. is a clinical stage bioelectric MedTech company focused on delivering transcutaneous spinal neuromodulation technologies to improve the lives of people with neurological conditions such as paralysis and urinary dysfunction. According to its website, Spinex Inc. is committed to developing medical equipment and devices that leverage spinal neuromodulation for recovery from spinal cord injuries and related disorders.
Spinex Inc. has received several significant federal grant awards to advance its transcutaneous electrical spinal cord neuromodulation (TESCON) technologies for various clinical applications. The National Institute of Child Health and Human Development awarded Spinex a $1.8 million Project Grant to conduct a clinical study investigating the use of TESCON combined with activity-based neurorehabilitation therapy to improve voluntary motor function in children with spastic cerebral palsy. The National Science Foundation funded a $255,568 grant for Spinex to develop a transcutaneous spinal cord neuromodulator device for home use and non-invasive pain management. Additionally, the National Institute of Diabetes and Digestive and Kidney Diseases provided a $4.7 million award to develop and clinically validate a TESCON device for mitigating neurogenic bladder symptoms resulting from spinal cord injuries. This project involves building a commercial TESCON prototype and conducting a multicenter randomized controlled trial to demonstrate the device's ability to improve bladder function, diminish incontinence, and restore sensation in individuals with spinal cord injuries as evidence for an FDA 510(k) submission.
SBA capabilities narrative
SpineX Inc. is a seed-stage medical device company developing Neuromodulation devices leveraging cutting-edge research from the lab of Dr. V Reggie Edgerton, PhD at UCLA. Over 10M people in the US deal with some form of paralysis and these individuals suffer from lost sensation, bladder, bowel, sexual dysfunction, compromised trunk, hand and arm function and cardiovascular distress. Our proprietary, non-surgical neuromodulation system, TESCoN, can generate significant improvements for each of these issues.
Quick answers
Is Spinex Inc. registered in SAM.gov?
Spinex Inc.'s SAM.gov registration expired on September 26, 2025.
What is Spinex Inc.'s CAGE code?
Spinex Inc.'s CAGE code is 8BJG3, and its Unique Entity ID (UEI) is XNMDENJ7E211.
What is Spinex Inc.'s most recent federal award?
Spinex Inc.'s most recent federal grant award is Spinal cord innovation in pediatrics to treat cerebral palsy (scip clinical study) (R44HD112281), from National Institute of Child Health and Human Development (NIH), on September 22, 2023.
On GovTribe
See Spinex Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors